Correlation between efficacy of the biological therapy (tocilizumab) and levels of oxidative stress markers in Japanese patients with rheumatoid arthritis (inadequate responders to existing therapies)

Correlation between efficacy of the biological therapy (tocilizumab) and levels of oxidative stress markers in Japanese patients with rheumatoid arthritis (inadequate responders to existing therapies) - Correlation between efficacy of the biological therapy (tocilizumab) and levels of oxidative stress markers in Japanese patients with rheumatoid arthritis (inadequate responders to existing therapies)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017230

Enrollment

Registered

2015-04-22

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Biologic treatment (tocilizumab)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patient diagnosed as having rheumatoid arthritis according to ACR 1987 revised classification criteria for rheumatoid arthritis or ACR/EULAR 2010 revised classification criteria for rheumatoid arthritis. 2)Patients who received a full explanation upon participation in this study. 3)Based on the Japan College of Rheumatology "tocilizumab use guidelines for rheumatoid arthritis (RA) (2012 Revised Edition)", patients who meet the following criteria 1:Rheumatoid arthritis patients uncontrolled the use of existing anti-rheumatic drugs to continue the normal dose treatment for 3 months or more.

Exclusion criteria

Exclusion criteria: 1)The patients have an obvious infection in by just before treatment administration, and research investigator or research sharing doctor has determined that they are inappropriate for this study. 2)Based on the Japan College of Rheumatology "tocilizumab use guidelines for rheumatoid arthritis (2012 Revised Edition)", the patients correspond to the administration contraindication 3)The Patients who were considered as inappropriate by the other research doctors based on the medical backgrounds. 4)Under 20 years old

Design outcomes

Primary

Measure	Time frame
Levels of change in oxidative stress markers at 0, 6, and 12 months	—

Countries

Japan

Contacts

Public ContactHiroaki Niiro

Graduate School of Medical Sciences, Kyushu University Department of Medicine and Biosystemic Science

hniiro@med.kyushu-u.ac.jp0926425233

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026